A COST VARIATION COMPARISON AMONG ORAL ANTI-MIGRAINE DRUGS AVAILABLE IN THE INDIAN MARKET

AKASH MISHRA; POOJA SOLANKI MISHRA; ANJALI KUSHWAH; KAMAYANI GUPTA

doi:10.22159/ijpps.2024v16i5.50777

Authors

AKASH MISHRA Department of Pharmacology, MGM Medical College, Indore-452001, Madhya Pradesh, India https://orcid.org/0009-0008-5559-2935
POOJA SOLANKI MISHRA Department of Pharmacology, MGM Medical College, Indore-452001, Madhya Pradesh, India https://orcid.org/0009-0004-9598-4993
ANJALI KUSHWAH Department of Pharmacology, MGM Medical College, Indore-452001, Madhya Pradesh, India https://orcid.org/0000-0001-6450-1750
KAMAYANI GUPTA Department of Pharmacology, MGM Medical College, Indore-452001, Madhya Pradesh, India https://orcid.org/0000-0002-4745-0223

DOI:

https://doi.org/10.22159/ijpps.2024v16i5.50777

Keywords:

Anti-migraine drugs, Cost ratio, Cost percent variation, Migraine prophylaxis, Cost analysis

Abstract

Objective: Our study aimed to evaluate the cost percent variation and cost ratio of different brands of oral anti-migraine drugs available in Indian market.

Methods: The cost of various commonly used oral anti-migraine drugs were taken from the latest issue of Current Index of Medical Specialities January 2022, Drug Today January-April 2022 and 1 mg online site. Cost percent variation and Cost ratio were calculated.

Results: A total of 7 single anti-migraine drugs and 9 Fixed-Dose Combinations (FDCs) showed a wide range of cost variation. The highest cost percent variation of 433% was seen in Sumatriptan 50 mg with a cost ratio of 5.33, whereas Amitriptyline 10 mg showed the lowest cost percent variation of 47.9% with a cost ratio of 1.47. Among FDCs Naproxen 500 mg+Sumatriptan 85 mg showed the highest cost per cent variation of 400% with a cost ratio of 5.25 and Propranolol 40 mg+Flunarizine 10 mg showed the lowest cost per cent variation of 46.56% with a cost ratio of 1.46.

Conclusion: Our study showed a wide variation in the cost of oral anti-migraine drugs available in the Indian market, which provides insight to the healthcare professional and gives Drug Price Control Order (DPCO) authorities to minimize the financial burden and improve patient compliance.

Downloads

Download data is not yet available.

References

Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z, Lifting the Burden: the Global Campaign against Headache. Migraine remains second among the world’s causes of disability and first among young women: findings from GBD2019. J Headache Pain. 2020 Dec 2;21(1):137. doi: 10.1186/s10194-020-01208-0, PMID 33267788, PMCID PMC7708887.

GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018 Nov;17(11):954-76. doi: 10.1016/S1474-4422(18)30322-3, PMID 30353868, PMCID PMC6191530.

Berg J. Economic evidence in migraine and other headaches: a review. Eur J Health Econ. 2004 Oct;5Suppl 1:S43-54. doi: 10.1007/s10198-005-0288-z, PMID 15754073.

Lanteri Minet MM. Economic burden and costs of chronic migraine. Curr Pain Headache Rep. 2014 Jan;18(1):385. doi: 10.1007/s11916-013-0385-0, PMID 24338699.

Lanteri Minet MM, Duru G, Mudge M, Cottrell S. Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review. Cephalalgia. 2011 May;31(7):837-50. doi: 10.1177/0333102411398400, PMID 21464078.

GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019 May;18(5):459-80. doi: 10.1016/S1474-4422(18)30499-X, PMID 30879893, PMCID PMC6459001.

Headache: Dennis L. Kasper. Harrison’s Manual of Medicine, 19th ed. 2016. Available from: https://accessmedicine.mhmedical.com/content.aspx?bookid=1820&sectionid=127554784

Das SC, Mandal M, Mandal SC. A critical study of availability and cost variation between different brands: impact on access to medicines. Indian J Pharm Sci. 2007;69(1):158-63.

Waldo DR. Outpatient prescription drug spending by the Medicare population. Health Care Financ Rev. 1987 Fall;9(1):83-9. PMID 10312274, PMCID PMC4192897.

Ahmad A, Patel I, Parimilakrishnan S, Mohanta GP, Chung H, Chang J. The role of pharmacoeconomics in the current Indian healthcare system. J Res Pharm Pract. 2013 Jan;2(1):3-9. doi: 10.4103/2279-042X.114081, PMID 24991597, PMCID PMC4076893.

Current Index of Medical Specialties, UBM Medica India Pvt. Ltd; 2022.

Drug Today, Lorina Publications (India) Inc; 2022.

Tiwari A, Reddy P. Cost analysis of antifungal drugs available in India: a pharmacoeconomic perspective. Indian J Pharm Pharmacol. 2016;3(4):192-6.

Gupta P, Sankdia RK, Marko S, Dubey L. A cost variation analysis of oral and topical antifungal agents available for the treatment of superficial fungal infections in India-an insight to the rising treatment cost. Asian J Pharm Clin Res 2022;15:123-6. doi: 10.22159/ajpcr.2022.v15i7.45467.

Rani V, Venepally S. A cost variation analysis study of drugs used in the management of benign prostatic hyperplasia available in the Indian market. Asian J Pharm Clin Res. 2021 Mar;14:152-5. doi: 10.22159/ajpcr.2021.v14i6.41291.

Roy V, Gupta U, Gupta M, Agarwal AK. Prescribing practices in private health facilities in Delhi (India). Indian J Pharmacol. 2013 Sep-Oct;45(5):534-5. doi: 10.4103/0253-7613.117762, PMID 24130397, PMCID PMC3793533.

Allan GM, Lexchin J, Wiebe N. Physician awareness of drug cost: a systematic review. PLOS Med. 2007 Sep;4(9):e283. doi: 10.1371/journal.pmed.0040283. PMID 17896856, PMCID PMC1989748.

King DR, Kanavos P. Encouraging the use of generic medicines: implications for transition economies. Croat Med J. 2002 Aug;43(4):462-9, PMID 12187525.

Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart MA, Choudhry NK. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA. 2008 Dec 3;300(21):2514-26. doi: 10.1001/jama.2008.758, PMID 19050195, PMCID PMC2713758.

Tilyard MW, Dovey SM, Rosenstreich D. General practitioners’ views on generic medication and substitution. N Z Med J. 1990 Jul 11;103(893):318-20. PMID 2371006.

Davit BM, Nwakama PE, Buehler GJ, Conner DP, Haidar SH, Patel DT. Comparing generic and innovator drugs: a review of 12 y of bioequivalence data from the United States Food and Drug Administration. Ann Pharmacother. 2009 Oct;43(10):1583-97. doi: 10.1345/aph.1M141, PMID 19776300.

Shrank WH, Cox ER, Fischer MA, Mehta J, Choudhry NK. Patients’ perceptions of generic medications. Health Aff (Millwood). 2009 Mar-Apr;28(2):546-56. doi: 10.1377/hlthaff.28.2.546, PMID 19276015, PMCID PMC2748784.

Singal GL, Nanda A, Kotwani A. A comparative evaluation of price and quality of some branded versus branded-generic medicines of the same manufacturer in India. Indian J Pharmacol. 2011 Apr;43(2):131-6. doi: 10.4103/0253-7613.77344, PMID 21572645, PMCID PMC3081449.

Wertheimer AI, Grumer SK. Overview of international pharmacy pricing. Pharmacoeconomics. 1992 Dec;2(6):449-55. doi: 10.2165/00019053-199202060-00005, PMID 10172052.

Roy V, Gupta U, Agarwal AK. Cost of medicines and their affordability in private pharmacies in Delhi (India). Indian J Med Res. 2012 Nov;136(5):827-35. PMID 23287131, PMCID PMC3573605.

Drug Cost Control Order. Government of India; 2013. Available from: http://www.nppaindia.nic.in/DPCO2013.pdf [Last accessed on 19 Dec 2016]

Kotwani A. Commentary: will generic drug stores improve access to essential medicines for the poor in India? J Public Health Policy. 2010;31(2):178-84. doi: 10.1057/jphp.2010.2, PMID 20535100.

Kotwani A. Commentary: will generic drug stores improve access to essential medicines for the poor in India? J Public Health Policy. 2010 Jul;31(2):178-84. doi: 10.1057/jphp.2010.2, PMID 20535100.